Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.
Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas D, Panagiotidis I, Kafantari E, Giannouli S, Zomas A, Konstantopoulos K, Dimopoulos MA. Kastritis E, et al. Among authors: ziogas d. Haematologica. 2017 Mar;102(3):593-599. doi: 10.3324/haematol.2016.145078. Epub 2016 Oct 27. Haematologica. 2017. PMID: 27789676 Free PMC article.
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, Matsouka C, Mparmparousi D, Gika D, Kafantari E, Ziogas D, Fotiou D, Panagiotidis I, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: ziogas d. Am J Hematol. 2016 May;91(5):499-502. doi: 10.1002/ajh.24335. Epub 2016 Apr 4. Am J Hematol. 2016. PMID: 26890495 Free article. Clinical Trial.
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Terpos E, Migkou M, Christoulas D, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Iakovaki M, Panagiotidis I, Ziogas DC, Fotiou D, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: ziogas dc. Blood Cancer J. 2016 May 27;6(5):e428. doi: 10.1038/bcj.2016.37. Blood Cancer J. 2016. PMID: 27232930 Free PMC article.
Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens.
Ziogas DC, Kastritis E, Terpos E, Roussou M, Migkou M, Gavriatopoulou M, Spanomichou D, Eleutherakis-Papaiakovou E, Fotiou D, Panagiotidis I, Kafantari E, Psimenou E, Boletis I, Vlahakos DV, Gakiopoulou H, Matsouka C, Dimopoulos MA. Ziogas DC, et al. Leuk Lymphoma. 2017 Aug;58(8):1832-1839. doi: 10.1080/10428194.2016.1267349. Epub 2016 Dec 14. Leuk Lymphoma. 2017. PMID: 27967286
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.
Kastritis E, Gavriatopoulou M, Roussou M, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Panagiotidis I, Giannouli S, Psimenou E, Marinaki S, Apostolou T, Gakiopoulou H, Tasidou A, Papassotiriou I, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: ziogas dc. Am J Hematol. 2017 Jul;92(7):632-639. doi: 10.1002/ajh.24738. Epub 2017 May 26. Am J Hematol. 2017. PMID: 28370245 Free article.
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib.
Kastritis E, Gavriatopoulou M, Roussou M, Fotiou D, Ziogas DC, Migkou M, Eleutherakis-Papaiakovou E, Panagiotidis I, Kanellias N, Psimenou E, Papadopoulou E, Pamboucas C, Manios E, Gakiopoulou H, Ntalianis A, Tasidou A, Giannouli S, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: ziogas dc. Blood Cancer J. 2017 Jun 16;7(6):e570. doi: 10.1038/bcj.2017.47. Blood Cancer J. 2017. PMID: 28622303 Free PMC article.
Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.
Dimopoulos MA, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M, Panagiotidis I, Eleutherakis-Papaiakovou E, Kanellias N, Psimenou E, Marinaki S, Bacharaki D, Mparmparoussi D, Matsouka C, Giannouli S, Terpos E, Kastritis E. Dimopoulos MA, et al. Among authors: ziogas dc. Blood Cancer J. 2017 Jun 16;7(6):e571. doi: 10.1038/bcj.2017.49. Blood Cancer J. 2017. PMID: 28622304 Free PMC article. Clinical Trial. No abstract available.
Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.
Ziogas DC, Terpos E, Gavriatopoulou M, Migkou M, Fotiou D, Roussou M, Kanellias N, Tatouli I, Eleutherakis-Papaiakovou E, Panagiotidis I, Ntanasis-Stathopoulos I, Kastritis E, Dimopoulos MA. Ziogas DC, et al. Leuk Lymphoma. 2018 Apr;59(4):983-987. doi: 10.1080/10428194.2017.1361031. Epub 2017 Aug 7. Leuk Lymphoma. 2018. PMID: 28782413 No abstract available.
Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis.
Eleutherakis-Papaiakovou E, Dimopoulos MA, Kastritis E, Christoulas D, Roussou M, Migkou M, Gavriatopoulou M, Fotiou D, Panagiotidis I, Ziogas DC, Kanellias N, Papadimitriou C, Terpos E. Eleutherakis-Papaiakovou E, et al. Among authors: ziogas dc. Bone Marrow Transplant. 2017 Nov;52(11):1537-1542. doi: 10.1038/bmt.2017.172. Epub 2017 Aug 14. Bone Marrow Transplant. 2017. PMID: 28805791
202 results